Enhancement the eff ec- tiveness of therapy of the new COVID-19 coronavirus infection using interferon alpha-2b in adults

   In order to assess the clinical eff ectiveness of COVID-19 complex therapy in adults, 140 patients with a confi rmed diagnosis of a new coronavirus infection, clinical symptoms and lung damage from 25 to 75 % (mild and moderate form) hospitalized in budgetary healthcare institutions of the Omsk region were included in an open prospective observational study. Patients were evenly divided into two groups: 1 — received standard therapy in accordance with the Temporary Guidelines "Prevention, diagnosis and treatment of new coronavirus infection (COVID-19)" approved by the Ministry of Health of the Russian Federation and interferon alpha-2b preparations (Viferon ® rectal suppositories 3,000,000 IU and Viferon ® gel for external and topical use of 36,000 IU/g); 2 — received only standard therapy. In group 1 patients, elimination of the SARS-CoV-2 antigen from the nasopharyngeal mucosa occurred 2 days earlier than in group 2 patients. Also, patients receiving standard therapy and interferon alpha-2b preparations improved on average 4.5 days earlier, most of the main symptoms of the disease were stopped by the 6th day of therapy. It was noted that in patients receiving complex standard therapy with adding of interferon alpha-2b preparations, a more pronounced regression of lung tissue damage was observed, especially in patients with a high degree of their lesion according to CT data before hospitalization. By the end of treatment in group 1, the proportion of patients with lung tissue lesions of grade CT-3 signifi cantly decreased by 17%, while in group 2, the proportion of patients with CT-3 increased by 13 %. Analysis of the dynamics of laboratory parameters and the main markers of infl ammation in the therapy groups also confi rms the positive eff ect of the inclusion of interferon alpha-2b drugs in the standard therapy. No adverse events associated with the use of interferon alpha-2b preparations were registered. Thus, in patients receiving standard therapy and interferon alpha-2b preparations, recovery occurred in a shorter time. In the end, this contributed to a faster discharge from the hospital and a reduction in the burden on the bed fund and medical staff . The results obtained give grounds to recommend the inclusion of interferon alpha-2b preparations (Viferon ® rectal suppositories 3,000,000 IU and Viferon ® gel for external and topical use 36,000 IU/g) in standard COVID-19 therapy regimens in adult patients with mild and moderate forms of the disease.

1. Lu C. C., Chen M. Y., Lee W. S., Chang Y. L. Potential therapeutic agents against COVID-19: What we know so far. J. Chin. Med. Assoc. 2020; 83 (6): 534–536. DOI: 10.1097/JCMA.0000000000000318

2. Mehra M. R., Desai S. S., Ruschitzka F. Patel RETRACTED: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet. 2020; 22: S0140–6736(20)31180–6. DOI: 10.1016/S0140-6736(20)31180-6

3. Cao B., Wang Y., Wen D., Liu W., Wang J., Fan G. et al. A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19. N. Engl. J. Med. 2020; 382: 1787–99.32187464. DOI: 10.1056/NEJMoa2001282

4. Mary A., Hénaut L., Macq P. Y., Badoux L., Cappe A., Porée T. et al. Rationale for COVID-19 Treatment by Nebulized Interferon-β-1b-Literature Review and Personal Preliminary Experience. Front Pharmacol. 2020; 11: 592543. DOI: 10.3389/fphar.2020.592543

5. Pereda R., González D., Rivero H. B., Rivero J. C., Pérez A., Lopez L. D. R. et al. Therapeutic Effectiveness of Interferon Alpha 2b Treatment for COVID-19 Patient Recovery. J. Interferon Cytokine Res. 2020; 40 (12): 578–588. DOI: 10.1089/jir.2020.0188

6. Zhou Q., Chen V., Shannon C. P., Wei X. S., Xiang X., Wang X. et al. Interferon-α2b Treatment for COVID-19. Front Immunol. 2020; 11: 1061. DOI: 10.3389/fimmu.2020.01061

7. Busnadiego I., Fernbach S., Pohl M. O., Karakus U., Huber M., Trkola A. et al. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2. mBio. 2020; 11 (5): e01928–20. DOI: 10.1128/mBio.01928-20

8. Государственный реестр лекарственных средств Российской Федерации. [State Register of Medicines of the Russian Federation. (In Russian)]. [Electronic resource]. URL: https://grls.rosminzdrav.ru/Default.aspx

9. Временные клинические рекомендации. Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19). Версия 9 (26. 10. 2020). – М. [Temporary clinical recommendations. Prevention, diagnosis and treatment of new coronavirus infection (COVID-19). Version 9 (10/26/2020): M. (In Russian)].

10. Бочарова И. И. Профилактика ОРВИ у новорожденных детей и их матерей в условиях пандемии новой коронавирусной инфекции / И. И. Бочарова [и др.] // Вопросы гинекологии, акушерства и перинатологии. – 2021. – 20 (2): 66–74. [Bocharova I. I., Zarochentseva N. V., Aksenov A. N., Malinovskaya V. V., Vyzhlova E. N., Semenenko T. A., Suvorov A. Yu. Prevention of acute respiratory viral infections in newborns and their mothers in a pandemic of a new coronavirus infection. Voprosy ginekologii, akusherstva i perinatologii. 2021; 20 (2): 66–74. (In Russian)]. DOI: 10.20953/1726-1678-2021-2-66-74

11. Тимченко В. Н. Роль ранней этиологической расшифровки острых респираторных вирусных инфекций в выборе противовирусной терапии у детей в условиях стационара / В. Н. Тимченко [и др.] // Педиатрия им. Г. Н. Сперанского. – 2020. – 99 (1). – С. 15–22. [Timchenko V. N., Sukhovetskaya V. F., Chernova T. M., Barakina E. V., Pochinyaeva L. M., Malinovskaya V. V., Semenenko T. A., Shuvalov A. N. The role of early etiological interpretation of acute respiratory viral infections in the choice of antiviral therapy in children in hospital. Pediatriya. Zhurnal im. G. N. Speranskogo. 2020; 99 (1): 15–22. (In Russian)]. DOI: 10.24110/0031-403X-2020-99-1-100-106

12. Малиновская В. В. Местные формы препарата интерферона альфа-2b с антиоксидантами в профилактике острых респираторных инфекций в организованных воинских коллективах в условиях пандемии COVID-19 / В. В. Малиновская, Т. А. Семененко, И. В. Коржов // Морская медицина. – 2020. – 6 (3): 60–66. [Malinovskaya V. V., Semenenko T. A., Korzhov I. V. Local forms of the drug interferon alpha-2b with antioxidants in the prevention of acute respiratory infections in organized military collectives in the conditions of the COVID-19 pandemic. Morskaya medicina. 2020; 6 (3): 60–66. (In Russian)]. DOI: 10.22328/2413-5747-2020-6-3-60-66

13. MacFarland, Thomas W., Yates, Jan M. Using R for Biostatistics. Springer International Publishing, 2021. DOI: 10.1007/978-3-030-62404-0

14. Lepš J., Šmilauer P. Biostatistics with R: An Introductory Guide for Field Biologists. Cambridge: Cambridge University Press, 2020. DOI: 10.1017/9781108616041